Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6551
    +0.0028 (+0.43%)
     
  • OIL

    83.83
    +0.26 (+0.31%)
     
  • GOLD

    2,358.30
    +15.80 (+0.67%)
     
  • Bitcoin AUD

    98,246.95
    +544.38 (+0.56%)
     
  • CMC Crypto 200

    1,389.26
    -7.28 (-0.52%)
     
  • AUD/EUR

    0.6095
    +0.0022 (+0.36%)
     
  • AUD/NZD

    1.0980
    +0.0022 (+0.20%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,117.15
    +38.29 (+0.47%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,043.19
    +125.91 (+0.70%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Should You Buy Global Blood Therapeutics Before This Week's Earnings?

Should You Buy Global Blood Therapeutics Before This Week's Earnings?

Global Blood Therapeutics (NASDAQ: GBT) plans to report its first quarter earnings on Wednesday, May 6. Importantly, investors will see the first full quarter of sales for Oxbryta, the company's recently approved drug for adults and children age 12 and older with sickle cell disease. The Food and Drug Administration (FDA) approved Oxbryta on Nov. 25., three months before the FDA's Priority Review action date for the decision.